Lantern Pharma (LTRN) Receivables - Other (2019 - 2020)
Lantern Pharma's (LTRN) quarterly Receivables - Other came in at $11000.0 in Q4 2020, little changed on a YoY basis from $11000.0 in Q1 2020, and little changed quarter-over-quarter from $11000.0 in Q3 2020.
Powered by 
Analysis
Lantern Pharma (LTRN) Receivables - Other (2019 - 2020) Analysis & Trends
Lantern Pharma (LTRN) has reported Receivables - Other for 2 consecutive years, with $11000.0 the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Receivables - Other changed 0.0% year-over-year to $11000.0; the trailing twelve-month figure through Dec 2020 stood at $11000.0 (changed 0.0% YoY), and the FY2020 full-year result was $11000.0, changed 0.0% from the prior year.
- Receivables - Other steadied at $11000.0 in Q4 2020 per LTRN's latest filing, from $11000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $11000.0 in Q4 2019 and bottomed at $11000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lantern Pharma | 21.99 Mn | 21.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 11,000.00 |
| Sep 30, 2020 | 11,000.00 |
| Jun 30, 2020 | 11,000.00 |
| Dec 31, 2019 | 11,000.00 |